NCT05001724 2023-04-25KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentJiangsu Alphamab Biopharmaceuticals Co., LtdPhase 2/3 Terminated16 enrolled